Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.